The content on this site is intended for healthcare professionals only
Dr Yu Hu presents data from a study looking at bispecific CAR-T Cell therapy in patients with multiple myeloma during a press conference at ASH 2019.
The study evaluated the sustainability of remissions in this hard to treat multiple myeloma.
Read more about the study here.
Watch our interview with Dr Yu Hu here.
Understanding the remaining unmet needs in a post ASCT NDMM setting
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
Novel CAR-T cell therapy shows promise against calreticulin mutant neoplasms
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
Multiple myeloma in a resource constrained setting
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
